Sawai Group Holdings Co Ltd

Sawai Group Holdings maintains a capital structure with a debt-to-equity ratio of 0.55, indicating moderate leverage. The company's liquidity position is characterized by a current ratio of 1.95, suggesting it can cover its short-term obligations. However, the company's free cash flow is negative at -16.17 billion JPY, and capital expenditures are -27.51 billion JPY, indicating significant reinvestment in operations. In terms of profitability, Sawai Group Holdings reports a return on equity (ROE) of 6.88% and a return on assets (ROA) of 3.38%. These figures are below the typical thresholds for high-performing pharmaceutical firms, suggesting that the company is not generating returns at the upper end of the industry spectrum. The company's gross profit margin is 29.81%, and its operating margin is 2.15%, which are in line with the industry's median metrics. Geographically, Sawai Group Holdings is primarily focused on the Japanese market, with a significant portion of its revenue derived from domestic operations. The company does not disclose detailed segment revenue breakdowns, but its business is concentrated in the pharmaceuticals sector, with a focus on generic drugs and OTC products. Looking at growth, Sawai Group Holdings has reported a revenue of 189.02 billion JPY in the latest period. While the company's revenue is stable, there is no indication of significant growth in the near term. Analysts have provided a mean price target of 2,622.22 JPY, with a median of 2,700.00 JPY, suggesting a potential upside from the current market price of 1,768.00 JPY. The company faces several risk factors, including a negative net cash position after subtracting total debt, which could impact its financial flexibility. The risk of dilution is assessed as low, and no significant adjustments have been applied to the valuation metrics. The company's liquidity risk is moderate, and its credit risk is not explicitly quantified but is inferred from its leverage and cash flow position. Recent events and filings do not indicate any major changes in the company's strategic direction or financial health. The company continues to operate within its core pharmaceuticals business, with no significant new product launches or market expansions reported in the latest disclosures.